Abstract | PURPOSE: METHODS: RESULTS: Visual acuity and foveal thickness improved significantly in both the IRI group and the IAI group. In addition, aqueous levels of VEGF and PlGF as well as MCP-1 and IL-6 decreased significantly over time in both groups. These parameters did not significantly differ between both groups. CONCLUSIONS: In CRVO patients, both ranibizumab and aflibercept achieved similar improvement in clinical parameters and similar reductions in aqueous VEGF, PlGF, MCP-1, and IL-6 levels.
|
Authors | Osamu Kotake, Hidetaka Noma, Kanako Yasuda, Ryosuke Motohashi, Hiroshi Goto, Masahiko Shimura |
Journal | Ophthalmic research
(Ophthalmic Res)
Pg. 1-8
(May 25 2018)
ISSN: 1423-0259 [Electronic] Switzerland |
PMID | 29804112
(Publication Type: Journal Article)
|
Copyright | © 2018 S. Karger AG, Basel. |